Oragenics Inc. (OGEN) is a publicly traded Healthcare sector company. As of July 26, 2026, OGEN trades at $0.51 with a market cap of $2.31M and a P/E ratio of -0.11. OGEN moved +1.17% today. Year to date, OGEN is -34.75%; over the trailing twelve months it is -64.27%. Its 52-week range spans $0.50 to $18.90. Rallies surfaces OGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Oragenics Activates Three Australian Phase IIa Sites, Holds $6.1 M Cash and Signs LOI: Oragenics has activated three Australian Phase IIa sites for ONP-002, dosing its first concussion patient at Mackay and enrolling at Alfred and Adelaide with zero serious adverse events. The company holds $6.1 million cash and signed an LOI for a complementary CNS medical device licensing agreement.
| Metric | Value |
|---|---|
| Price | $0.51 |
| Market Cap | $2.31M |
| P/E Ratio | -0.11 |
| EPS | $-4.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.90 |
| 52-Week Low | $0.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-9.84M |
| Gross Margin | 0.00% |
OGEN analyst coverage data. Average price target: $0.00.